Research
Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.
StrongSupportsHIGH confidence
Tirzepatide is a dual GIP and GLP-1 RA... These trials have showed a mean weight loss of 12.8–25.3%... Semaglutide was approved by the FDA in 2024 as the first GLP-1RA to reduce CVD mortality in individuals with overweight and obesity regardless of diabetes status
Why this rating
Based on multiple RCTs (STEP, SURMOUNT, SELECT) and FDA approvals.
Source
Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization
Vidhi Singh et al. · Advances in Therapy · 2025
narrative_reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →